Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy

INTRODUCTION: Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease commonly caused by pathogenic genetic variants encoding sarcomere proteins. Mavacamten, a first-in-class allosteric inhibitor of cardiac-specific myosin, has demonstrated efficacy and safety in international clinical tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Zhuang, Wang, Fang, Jin, Wei, Zhang, Qing, Zhou, Jingmin, Yang, Ping, Wang, Geng, Hsu, Peiwen, Sun, Jing, Zhang, Shuyang, Han, Yaling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314621/
https://www.ncbi.nlm.nih.gov/pubmed/37336533
http://dx.doi.org/10.1136/bmjopen-2022-071473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314621/
https://www.ncbi.nlm.nih.gov/pubmed/37336533
http://dx.doi.org/10.1136/bmjopen-2022-071473

Ejemplares similares